However, as of 2016, phenotypic and genomic characteristics of gliomas, such as isocitrate dehydrogenase 1/2 (IDH1/2) mutation status and co-deletion of 1p/19q chromosomal regions, have been incorporated into classification, grading, prognosis, and determination of response to therapy [5]. This evidence concerns the gene IDH1 and central nervous system cancer.